Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
A6NHL2
UPID:
TBAL3_HUMAN
Alternative names:
-
Alternative UPACC:
A6NHL2; B4DKL2; Q4QQJ5; Q9H6Z0
Background:
Tubulin alpha chain-like 3 is a pivotal component of microtubules, essential for their assembly and dynamic structural alterations. These microtubules are integral to cell shape, division, and intracellular transport, showcasing the protein's critical role in cellular architecture and function.
Therapeutic significance:
Understanding the role of Tubulin alpha chain-like 3 could open doors to potential therapeutic strategies. Its central function in microtubule assembly positions it as a key target for interventions in cell division-related diseases.